Member
1 Award
Omniox
Omniox is an IND-stage biotherapeutics company focused on developing innovative H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles. These biologics are designed to safely deliver oxygen to hypoxic tissues, addressing significant unmet medical needs and improving patient outcomes.
Industries
biotechnology
health-diagnostics
therapeutics
Nr. of Employees
small (1-50)
Awards
Fiscal Year 2024 Military Prototype Advancement Initiative (MPAI)
OMX - A Novel Oxygen Carrier for Non-compressible Torso Hemorrhage in Austere Environments
Funding (ceiling)
$3,431,597.93
Award Year
2024
Patents
Products
Protein-based oxygen delivery therapeutic candidates
Lead biologic candidates based on engineered heme-binding proteins designed to bind and retain oxygen until reaching hypoxic microenvironments, with tunable oxygen affinity, circulation half-life, and tissue penetration profiles.
Protein-based oxygen delivery therapeutic candidates
Lead biologic candidates based on engineered heme-binding proteins designed to bind and retain oxygen until reaching hypoxic microenvironments, with tunable oxygen affinity, circulation half-life, and tissue penetration profiles.
Expertise Areas
- Therapeutic protein engineering
- Oxygen-delivery therapeutics
- Preclinical and IND-stage development
- Process and analytical development for biologics
Key Technologies
- Heme-binding protein engineering
- Protein engineering for oxygen carriers
- Oxygen-affinity tuning
- Protein structural biology
Key People
Jonathan Winger, PhD
Co-Founder and CEO
Julia Simmons
Senior Director, Controller
Alexandra Loucks
Director, Program Management
Jonathan Winger, PhD
Co-Founder and CEO
Julia Simmons
Senior Director, Controller
Alexandra Loucks
Director, Program Management